AbbVie Ventures now focuses on five therapeutic growth pillars in its strategic core: oncology, immunology, neuroscience, aesthetics, and eye care (Fig. 1). Across those pillars, the group is ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...

When the share price rose above $200 last year, the dividend - usually one of AbbVie's core strengths - looked a little less attractive. Today, after the Cerevel correction, the yield is a solid 3 ...